Literature DB >> 27322697

Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Matthew P Deek1, Sinae Kim2,3, Inaya Ahmed1, Bruno S Fang4, Wei Zou1, Jyoti Malhotra5, Joseph Aisner5, Salma K Jabbour1.   

Abstract

OBJECTIVE: The aim of this study is to investigate the impact of missed chemotherapy administrations (MCA) on the prognosis of non-small cell lung cancer (NSCLC) patients treated with definitive chemoradiation therapy (CRT).
MATERIALS AND METHODS: In total, 97 patients with NSCLC treated with definitive CRT were assessed for MCA due to toxicities. Logistic regression was used to determine factors associated with MCA. Kaplan-Meier curves, log-rank tests, and Cox Proportional Hazards models were conducted.
RESULTS: MCA occurred in 39% (n=38) of the patients. Median overall survival was 9.6 months for patients with MCA compared with 24.3 months for those receiving all doses (P=0.004). MCA due to decline in performance status was associated with the worst survival (4.6 mo) followed by allergic reaction (10.0 mo), hematologic toxicity (11 mo), and esophagitis (17.2 mo, P=0.027). In multivariate models, MCA was associated with higher mortality (hazard ratio, 1.97; P=0.01) and worse progression-free survival (hazard ratio, 1.96; P=0. 009).
CONCLUSIONS: MCA correlated with worse prognosis and increased mortality. Methods to reduce toxicity may improve administration of all chemotherapy doses and increase overall survival in NSCLC treated with CRT.

Entities:  

Mesh:

Year:  2018        PMID: 27322697      PMCID: PMC5767542          DOI: 10.1097/COC.0000000000000293

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  25 in total

1.  Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial.

Authors:  J R Simpson; M E Francis; R Perez-Tamayo; R D Marks; D V Rao
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-04       Impact factor: 7.038

2.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Authors:  Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

4.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

5.  Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.

Authors:  Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman
Journal:  Breast Cancer Res Treat       Date:  2006-05-17       Impact factor: 4.872

6.  Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

Authors:  Hyman B Muss; Susan Woolf; Donald Berry; Constance Cirrincione; Raymond B Weiss; Daniel Budman; William C Wood; I Craig Henderson; Clifford Hudis; Eric Winer; Harvey Cohen; Judith Wheeler; Larry Norton
Journal:  JAMA       Date:  2005-03-02       Impact factor: 56.272

7.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.

Authors:  J D Cox; T F Pajak; S Asbell; A H Russell; J Pederson; R W Byhardt; B Emami; M Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-10-20       Impact factor: 7.038

Review 8.  Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Authors:  Nuran Senel Bese; Jolyon Hendry; Branislav Jeremic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

9.  TNM staging of lung cancer: a quick reference chart.

Authors:  O Lababede; M A Meziane; T W Rice
Journal:  Chest       Date:  1999-01       Impact factor: 9.410

10.  Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Authors:  H H Strøm; R M Bremnes; S H Sundstrøm; N Helbekkmo; O Fløtten; U Aasebø
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

View more
  7 in total

1.  Redefine the Role of Proton Beam Therapy for the Locally-Advanced Non-Small Cell Lung Cancer Assisting the Reduction of Acute Hematologic Toxicity.

Authors:  Xi Cao; Peilin Liu; Xian-Shu Gao; Shiyu Shang; Jiayu Liu; Zishen Wang; Mengmeng Su; Xuanfeng Ding
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

2.  Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.

Authors:  Christian L Barney; Nicholas Scoville; Eric Allan; Ahmet Ayan; Dominic DiCostanzo; Karl E Haglund; John Grecula; Terence Williams; Meng Xu-Welliver; Gregory A Otterson; Jose G Bazan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-11-23       Impact factor: 7.038

3.  Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity.

Authors:  Andrew Zhang; Matthew P Deek; Sinae Kim; Mutlay Sayan; Alison Grann; Raquel T Wagman; Usha Malhotra; Lara Hathout; Nrusingh Biswal; Yin Zhang; John Langenfeld; Timothy Kennedy; David A August; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2019-06

4.  A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).

Authors:  Shigeru Tanzawa; Sunao Ushijima; Kazuhiko Shibata; Takuo Shibayama; Akihiro Bessho; Kyoichi Kaira; Toshihiro Misumi; Kenshiro Shiraishi; Noriyuki Matsutani; Hisashi Tanaka; Megumi Inaba; Terunobu Haruyama; Junya Nakamura; Takayuki Kishikawa; Masanao Nakashima; Keiichi Iwasa; Keiichi Fujiwara; Tadashi Kohyama; Shoichi Kuyama; Naoki Miyazawa; Tomomi Nakamura; Hiroshi Miyawaki; Hiroo Ishida; Naohiro Oda; Nobuhisa Ishikawa; Ryotaro Morinaga; Kei Kusaka; Nobukazu Fujimoto; Toshihide Yokoyama; Kenichi Gemba; Takeshi Tsuda; Hideyuki Nakagawa; Hirotaka Ono; Tetsuo Shimizu; Morio Nakamura; Sojiro Kusumoto; Ryuji Hayashi; Hiroki Shirasaki; Nobuaki Ochi; Keisuke Aoe; Nobuhiro Kanaji; Kosuke Kashiwabara; Hiroshi Inoue; Nobuhiko Seki
Journal:  Ther Adv Med Oncol       Date:  2021-02-27       Impact factor: 8.168

5.  The Symptom Burden and Quality of Life in Cancer Patients in the Gaza Strip, Palestine: A Cross-Sectional Study.

Authors:  Yousuf ElMokhallalati; Enas Alaloul; Mohammed Shatat; Tasneem Shneewra; Saad El Massri; Omar Shaer; Samuel Relton; Hammoda Abu-Odah; Matthew J Allsop
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

6.  Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study).

Authors:  Shigeru Tanzawa; Tomonori Makiguchi; Sadatomo Tasaka; Megumi Inaba; Ryosuke Ochiai; Junya Nakamura; Koji Inoue; Takayuki Kishikawa; Masanao Nakashima; Keiichi Fujiwara; Tadashi Kohyama; Hiroo Ishida; Shoichi Kuyama; Naoki Miyazawa; Tomomi Nakamura; Hiroshi Miyawaki; Naohiro Oda; Nobuhisa Ishikawa; Ryotaro Morinaga; Kei Kusaka; Yosuke Miyamoto; Toshihide Yokoyama; Chiaki Matsumoto; Takeshi Tsuda; Sunao Ushijima; Kazuhiko Shibata; Takuo Shibayama; Akihiro Bessho; Kyoichi Kaira; Toshihiro Misumi; Kenshiro Shiraishi; Noriyuki Matsutani; Nobuhiko Seki
Journal:  Ther Adv Med Oncol       Date:  2022-07-29       Impact factor: 5.485

7.  Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 among cancer patients in Bosnia and Herzegovina: A single-center cross-sectional study.

Authors:  Timur Cerić; Emir Sokolović; Anes Pašić; Emina Borovac-Gurda; Velda Smajlbegović; Berisa Hasanbegović; Emina Bičakčić Filipović; Elma Kapisazović; Selma Sokolović; Semir Bešlija
Journal:  Bosn J Basic Med Sci       Date:  2022-09-16       Impact factor: 3.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.